Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Page 1
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventil

…

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence

…
Is the raised volume rapid thoracic compression technique ready for use in clinical trials in infants with cystic fibrosis?
Matecki S, Kent L, de Boeck K, Le Bourgeois M, Zielen S, Braggion C, Arets HG, Bradley J, Davis S, Sermet I, Reix P; respiratory function group of the European Cystic Fibrosis Society Clinical Trial Network. Matecki S, et al. Among authors: sermet i. J Cyst Fibros. 2016 Jan;15(1):10-20. doi: 10.1016/j.jcf.2015.03.015. Epub 2015 Apr 15. J Cyst Fibros. 2016. PMID: 25890589 Free article. Review.
We advise its use currently in phase I/II trials and as a secondary endpoint in phase III studies. We emphasise the need for (1) more short-term variability and longitudinal 'natural history' studies, and (2) robust reference values for commercially available devices....
We advise its use currently in phase I/II trials and as a secondary endpoint in phase III studies. We emphasise the need for (1) more short- …
Follow-up of 452 totally implantable vascular devices in cystic fibrosis patients.
Munck A, Malbezin S, Bloch J, Gerardin M, Lebourgeois M, Derelle J, Bremont F, Sermet I, Munck MR, Navarro J. Munck A, et al. Among authors: sermet i. Eur Respir J. 2004 Mar;23(3):430-4. doi: 10.1183/09031936.04.00052504. Eur Respir J. 2004. PMID: 15065834 Free article.
The mean functional time per device was 32 +/- 25 months. Long-term complications occurred with 188 devices (42%); they consisted mainly of occlusion (21%, requiring removal in 77%), infection (9.3%, requiring removal in 851%; septicaemia in 7.3%; rate 0.3 per 1,000 days, …
The mean functional time per device was 32 +/- 25 months. Long-term complications occurred with 188 devices (42%); they consisted mai …